Dr. KAYI CANGIR is a Professor in the Department of Thoracic Surgery at Ankara University , TURKEY. She graduated from Ankara University Medical School in 1991. She followed specialty training in thoracic surgery at the Ankara University and was board-certified in thoracic surgery in 1998. She became associate professor in 2005 and professor in 2012.

Her areas of expertise include lung cancer, malignant mesothelioma, thymic tumors, esophegeal cancer and surgical treatment of thoracic outlet syndorme. She is a member of several national and international medical societies. She has been member of the International Association for the Study of Lung Cancer since 2009. Dr. Kayı Cangır is a member of the IASLC Lung Staging and Prognostic Factors Committee, the IASLC the Mesothelioma Committee and IASLC Thymic Malignancy Staging and Prognostic Factors Committee.

She has multiple publications on prognostic factors, staging, radiomics-histologic correlation, and surgical treatment of lung cancer, thymic epithelial tumors,and MPM.

Dr. Christopher Manley is the Director of Interventional Pulmonology at Fox Chase Cancer Center in Philadelphia. He graduated with honors in bioethics and research from Loyola Stritch School of Medicine then completed fellowships in pulmonary/critical care at Tufts Medical Center and interventional pulmonary at the Harvard Combined (MGH/BIDMC) Program. Under Dr Manley’s leadership, Fox Chase became one of the first three hospitals in the country to develop a robotic bronchoscopy program and has remained one of the most robust robotic bronchoscopy programs in the country. Dr. Manley’s research interests include bronchoscopic imaging utilizing intra-tumoral confocal microscopy, cost-value analysis, and improving yield of small biopsy specimens. Dr. Manley is one of Philadelphia Magazine’s Top Doctors in Philadelphia and his work with the Monarch was recognized by Life Sciences Pennsylvania with the Patient Impact Award 2020.

Dr. Sarah Goldberg is an Associate Professor of Medicine in the division of Medical Oncology at the Yale School of Medicine and Yale Cancer Center. She specializes in the treatment of thoracic malignancies and is the Research Director of the Center for Thoracic Cancers and the Associate Director of the Hematology/Oncology Fellowship Program at Yale. Her research interests include personalized medicine and immunotherapy for non-small cell lung cancer and identification of biomarkers that predict response to treatment.

Prof. Aleš Ryška, MD, PhD, is the head of the Fingerland Department of Pathology at Charles University, Medical Faculty in Hradec Králové, Czech Republic. He received his medical degree and PhD in pathology from the Charles University, Medical Faculty. Prof. Ryška is board certified in pathology.

Prof. Ryška’s interests are in diagnostics of lesions of the breast, thyroid, and salivary glands, as well as in predictive pathology (detection of markers predicting response to targeted therapy) and quality control in pathology. He is a principal investigator and co-investigator of 17 research projects.

Prof. Ryška is a member of several scientific societies, including the International Academy of Pathology - Czech Division, the Society of Czech Pathologists, the European Society of Pathology, and the Czech Oncologic Society. He is also a member of several editorial boards of journals, including the Czech-Slovak Pathology and Forensic Medicine, Virchows Archiv, Clinical Oncology, Cytopathology, Pathology & Oncology Research. Prof. Ryška has authored and co-authored over 193 full-text articles in peer-reviewed journals, a book, and multiple book chapters.

Prof. Ryška has been an invited speaker to multiple national and international meetings (Czech Republic, Slovakia, Germany, Brazil, Hungary, Portugal, Romania, Serbia, Slovenia, Croatia, Austria, Australia, Poland, Macedonia, Jordan, Ireland, Bulgaria, France, Spain, Netherlands, UK, USA) and has tutored many courses at the European School of Pathology (thyroid gland pathology).

Dr. Afshin Dowlati earned his medical degree from the University of Liege School of Medicine, Belgium in 1992. He then went on to complete an internal medicine residency at the same institution in Belgium and completed a second internal medicine residency and fellowship in hematology and oncology at Case Western Reserve University School of Medicine, Ohio. In 2000, he joined University Hospitals Seidman Cancer Center, part of the Case Comprehensive Cancer Center at Case Western Reserve University, to lead the thoracic oncology program and in 2007 became Co-Leader of the Developmental Therapeutics Program.

Dr. Dowlati is the Rosalie and Morton A. Cohen Chair in Lung Cancer, the Lucile and Robert Gries Endowed Director of the Center for Lung Cancer Drug Development, and the Director of the Phase I and Thoracic Oncology programs at University Hospitals Seidman Cancer Center. Dr. Dowlati is also the Associate Director for Clinical Research at the Case Comprehensive Cancer Center. As professor of medicine and oncology at Case Western Reserve University, Dr. Dowlati’s scientific research focuses on genomics and signaling pathways in small cell lung cancer. His group was the first to describe a YAP1 positive subgroup of SCLC.

In recognition of his achievements, Dr. Dowlati has received numerous awards including being recognized as one of Cleveland Magazine’s Top Doctors for multiple years, receiving the prestigious Castle Connelly America’s Top Doctors for Cancer award on multiple occasions, and the Michaele C. Christian Oncology Drug Development Lectureship of the National Cancer Institute in 2012.

Antonio Passaro, MD, PhD, is a medical oncologist at the Division of Thoracic Oncology of the European Institute of Oncology in Milan, Italy. He received his medical degree in medicine and surgery and his PhD in molecular medicine, with a thesis on lung cancer, from the Sapienza University of Rome. Dr Passaro is board certified in medical oncology.

Dr Passaro is a clinician and translational researcher specializing in lung cancer. His main areas of research and clinical interest are predictive biomarker, in particular EGFR, and related target agents and immunotherapy agents, from discovery to validation in a clinical setting. His main research interests include studying the therapeutic relevance of oncogenic alterations in lung cancer. Dr Passaro is also very involved and interested in using target agents in uncommon molecular patients population and non-metastatic settings, alone or in a multimodality approach for early or locally-advanced disease. He is also involved in a portfolio of many clinical trials, sponsored and academic, investigating new anticancer agents.

Dr Passaro serves in several professional societies and committees, including the ESMO Council, Chair of the ESMO Press & Media Affairs Committee and as an AIOM (Italian Association of Medical Oncology) board member for lung cancer guidelines. He has authored several peer-reviewed manuscripts, serves on the editorial board of different clinical cancer journals, and acts as a reviewer for multiple lung cancer publications.